NASDAQ : FLNA

Filana Therapeutics, Inc. — Company profile

Other · United States

Last price 0.622 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 30.05M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Details

NameFilana Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees20
Founded1998
CeoRichard Barry
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS14817C1071
Cusip14817C107
Cik1069530
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Richard Jon BarryChief Executive Officer, President and Director
Eric J. SchoenChief Financial Officer
R. Christopher Cook J.D.Chief Operating and Legal Officer
Dr. George Thornton Ph.D.Senior Vice President of Technology
Michael ZamlootSenior Vice President of Technical Operations
Jaren LandenChief Clinical Development Officer
Dr. Angelique Bordey Ph.D.Senior Vice President of Neuroscience
Jack Moore Ph.D.Senior Vice President of Clinical Development
Dr. Joseph Hulihan M.D.Chief Medical Officer
Nancy TeasdaleHead of Regulatory Affairs

Contact

Address6801 N. Capital of Texas Highway, Building 1, Austin, Texas 78731, United States
Phone512 501 2444
Websitehttps://www.filanatx.com